This is not the most recent version of the article. View current version (16 OCT 2015)

Intervention Review

You have free access to this content

Antibiotics for acute maxillary sinusitis in adults

  1. Anneli Ahovuo-Saloranta1,*,
  2. Ulla-Maija Rautakorpi1,
  3. Oleg V Borisenko2,
  4. Helena Liira3,
  5. John W Williams Jr4,
  6. Marjukka Mäkelä5

Editorial Group: Cochrane Acute Respiratory Infections Group

Published Online: 11 FEB 2014

Assessed as up-to-date: 20 MAR 2013

DOI: 10.1002/14651858.CD000243.pub3


How to Cite

Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, Liira H, Williams Jr JW, Mäkelä M. Antibiotics for acute maxillary sinusitis in adults. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD000243. DOI: 10.1002/14651858.CD000243.pub3.

Author Information

  1. 1

    National Institute for Health and Welfare (THL), Tampere office, Finnish Office for Health Technology Assessment (FinOHTA), Tampere, Finland

  2. 2

    Synergus AB, Danderyd, Sweden

  3. 3

    University of Helsinki, Department of General Practice, Kirkkonummi, Finland

  4. 4

    Durham VAMC and Duke University Medical Center, Departments of Medicine and Psychiatry, Durham, NC, USA

  5. 5

    National Institute for Health and Welfare (THL), Finnish Office for Health Technology Assessment (FinOHTA), Helsinki, Finland

*Anneli Ahovuo-Saloranta, Finnish Office for Health Technology Assessment (FinOHTA), National Institute for Health and Welfare (THL), Tampere office, Finn-Medi 3, Biokatu 10, Tampere, FI-33520, Finland. anneli.ahovuo-saloranta@thl.fi.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 11 FEB 2014

SEARCH

This is not the most recent version of the article. View current version (16 OCT 2015)

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Antibiotics versus placebo, Outcome 1 Clinical failure defined as a lack of full recovery or improvement at 7 to 15 days of follow-up.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Antibiotics versus placebo, Outcome 2 Clinical failure defined as a lack of full recovery or improvement at 16 to 60 days of follow-up.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Antibiotics versus placebo, Outcome 3 Clinical failure defined as a lack of full recovery at 7 to 15 days of follow-up.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Antibiotics versus placebo, Outcome 4 Clinical failure defined as a lack of full recovery at 16 to 60 days of follow-up.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Antibiotics versus placebo, Outcome 5 Relapse rates after 60 days.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Antibiotics versus placebo, Outcome 6 Drop-outs due to adverse effects.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Cephalosporin/macrolide versus amoxicillin-clavulanate, Outcome 1 Ceph versus amox-clav; clinical failure defined as a lack of full recovery or improvement at 7 to 15 days of follow-up.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Cephalosporin/macrolide versus amoxicillin-clavulanate, Outcome 2 Ceph versus amox-clav; clinical failure defined as lack of full recovery or improvement at 16 to 60 days of follow-up.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Cephalosporin/macrolide versus amoxicillin-clavulanate, Outcome 3 Drop-outs due to adverse effects (cephalosporins).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Cephalosporin/macrolide versus amoxicillin-clavulanate, Outcome 4 Macrolides versus amox-clav; clinical failure defined as a lack of full recovery or improvement at 7 to 15 days of follow-up.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Cephalosporin/macrolide versus amoxicillin-clavulanate, Outcome 5 Macrolides versus amox-clav; clinical failure defined as a lack of full recovery or improvement at 16 to 60 days of follow-up.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Cephalosporin/macrolide versus amoxicillin-clavulanate, Outcome 6 Drop-outs due to adverse effects (macrolides).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Non-penicillin antibiotics versus beta-lactamase sensitive penicillins, Outcome 1 Clinical failure defined as a lack of full recovery or improvement at 7 to 15 days of follow-up.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Non-penicillin antibiotics versus beta-lactamase sensitive penicillins, Outcome 2 Clinical failure defined as a lack of full recovery or improvement at 16 to 60 days of follow-up.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Non-penicillin antibiotics versus beta-lactamase sensitive penicillins, Outcome 3 Drop-outs due to adverse effects.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Tetracyclines versus mixed classes of antibiotics, Outcome 1 Clinical failure defined as a lack of full recovery or improvement at 7 to 15 days of follow-up.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Tetracyclines versus mixed classes of antibiotics, Outcome 2 Drop-outs due to adverse effects.